Pharmacokinetics of recombinant bifunctional fusion proteins

Bibliography

• Meibohm B. Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. WILEY-VCH Verlag GmbH & Co. KGaA; Weinheim, FRG: 2006
   Google Scholar
• Duttaroy A, Kanakaraj P, Osborn B, Development of a long-acting insulin analog using albumin fusion technology. Diabetes 2005;54(1):251-8
   PubMedGoogle Scholar
• Osborn B, Olsen H, Nardelli B, Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002;303(2):540-8
   PubMed Web of Science ®Google Scholar
• Muller N, Schneider B, Pfizenmaier K, Superior serum half life of albumin tagged TNF ligands. Biochem Biophys Res Commun 2010;396(4):793-9
   PubMedGoogle Scholar
• Peters R, Low S, Kamphaus G, Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010;115(10):2057-64
   PubMed Web of Science ®Google Scholar
• Schmidt SR. Fusion-proteins as biopharmaceuticals–applications and challenges. Curr Opin Drug Discov Devel 2009;12(2):284-95
   PubMedGoogle Scholar
• Leader B, Baca Q, Golan D. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008;7(1):21-39
   PubMed Web of Science ®Google Scholar
• Martin ST, Tichy EM, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy 2011;31(4):394-407
   PubMed Web of Science ®Google Scholar
• Teng LS, Jin KT, He KF, Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc 2010;73(9):449-56
   PubMed Web of Science ®Google Scholar
• Aggarwal S. What's fueling the biotech engine-2007. Nat Biotechnol 2008;26(11):1227-33
   PubMedGoogle Scholar
• Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990;7(2):167-9
   PubMed Web of Science ®Google Scholar
• Brown LR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2005;2(1):29-42
   PubMedGoogle Scholar
• Widera A, Norouziyan F, Shen WC. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 2003;55(11):1439-66
   PubMed Web of Science ®Google Scholar
• Bai Y, Ann DK, Shen WC. Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc Natl Acad Sci USA 2005;102(20):7292-6
   PubMed Web of Science ®Google Scholar
• Amet N, Wang W, Shen WC. Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. J Control Release 2010;141(2):177-82
   PubMed Web of Science ®Google Scholar
• Bitonti AJ, Dumont JA, Low SC, Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004;101(26):9763-8
   PubMed Web of Science ®Google Scholar
• Vallee S, Rakhe S, Reidy T, Pulmonary administration of interferon Beta-1a-Fc fusion protein in non-human primates using an immunoglobulin transport pathway. J Interferon Cytokine Res 2011;32:1-7
   PubMedGoogle Scholar
• Reilly RM, Sandhu J, Alvarez-Diez TM, Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;28(2):126-42
   PubMed Web of Science ®Google Scholar
• Forero A, Weiden PL, Vose JM, Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004;104(1):227-36
   PubMed Web of Science ®Google Scholar
• Better M, Bernhard SL, Williams RE, T cell-targeted immunofusion proteins from Escherichia coli. J Biol Chem 1995;270(25):14951-7
   PubMedGoogle Scholar
• Syed S, Schuyler PD, Kulczycky M, Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997;89(9):3243-52
   PubMed Web of Science ®Google Scholar
• Hesketh P, Caguioa P, Koh H, Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 1993;11(9):1682-90
   PubMedGoogle Scholar
• Kelley VE, Bacha P, Pankewycz O, Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci USA 1988;85(11):3980-4
   PubMed Web of Science ®Google Scholar
• Ko YJ, Bubley GJ, Weber R, Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother 2004;27(3):232-9
   PubMed Web of Science ®Google Scholar
• Tang L, Persky AM, Hochhaus G, Pharmacokinetic aspects of biotechnology products. J Pharm Sci 2004;93(9):2184-204
   PubMed Web of Science ®Google Scholar
• Veng-Pedersen P, Gillespie W. Mean residence time in peripheral tissue: a linear disposition parameter useful for evaluating a drug's tissue distribution. J Pharmacokinet Biopharm 1984;12(5):535-43
   PubMedGoogle Scholar
• Straughn AB. Model-independent steady-state volume of distribution. J Pharm Sci 1982;71(5):597-8
   PubMedGoogle Scholar
• Perrier D, Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 1982;71(3):372-3
   PubMedGoogle Scholar
• Richter WF, Grimm HP, Theil FP. Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components. J Pharmacokinet Pharmacodyn 2011;38(5):581-93
   PubMedGoogle Scholar
• Yates JW, Arundel PA. On the volume of distribution at steady state and its relationship with two-compartmental models. J Pharm Sci 2008;97(1):111-22
   PubMed Web of Science ®Google Scholar
• Carnemolla B, Borsi L, Balza E, Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 2002;99(5):1659-65
   PubMed Web of Science ®Google Scholar
• Shin SU, Friden P, Moran M, Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci USA 1995;92(7):2820-4
   PubMedGoogle Scholar
• Zhou QH, Boado RJ, Lu JZ, Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab Dispos 2010;38(4):566-72
   PubMed Web of Science ®Google Scholar
• Gautier JF, Fetita S, Sobngwi E, Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005;31(3 Pt 1):233-42
   PubMed Web of Science ®Google Scholar
• Pasta P, Vecchio G, Carrea G. Conformation and proteolysis of glucagon and insulin in surfactant and lipid solutions. Biochim Biophys Acta 1988;953(3):314-20
   PubMedGoogle Scholar
• Baggio LL, Huang Q, Brown TJ, A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53(9):2492-500
   PubMed Web of Science ®Google Scholar
• Barrington P, Chien JY, Tibaldi F, LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011;13(5):434-8
   PubMed Web of Science ®Google Scholar
• Kim BJ, Zhou J, Martin B, Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Ther 2010;334(3):682-92
   PubMed Web of Science ®Google Scholar
• Schenk S, Schoenhals GJ, de Souza G, A high confidence, manually validated human blood plasma protein reference set. BMC Med Genomics 2008;1:41
   PubMed Web of Science ®Google Scholar
• Anderson PM, Sorenson MA. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 1994;27(1):19-31
   PubMed Web of Science ®Google Scholar
• Takagi A, Masuda H, Takakura Y, Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J Pharmacol Exp Ther 1995;275(2):537-43
   PubMed Web of Science ®Google Scholar
• Johnson V, Maack T. Renal extraction, filtration, absorption, and catabolism of growth hormone. Am J Physiol 1977;233(3):F185-96
   PubMed Web of Science ®Google Scholar
• Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984;27(3):351-7
   PubMed Web of Science ®Google Scholar
• Duttaroy A, Kanakaraj P, Osborn BL, Development of a long-acting insulin analog using albumin fusion technology. Diabetes 2005;54(1):251-8
   PubMedGoogle Scholar
• Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev 1998;19(5):608-24
   PubMed Web of Science ®Google Scholar
• Subramanian GM, Fiscella M, Lamouse-Smith A, Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007;25(12):1411-19
   PubMed Web of Science ®Google Scholar
• Osborn BL, Sekut L, Corcoran M, Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol 2002;456(1-3):149-58
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia a patients. Blood 2012; [Epub ahead of print]
   Google Scholar
• Dumont JA, Liu T, Low SC, Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia a mice and dogs. Blood 2012; [Epub ahead of print]
   Google Scholar
• Valentino LA. Recombinant FIXFc: a novel therapy for the royal disease? Expert Opin Biol Ther 2011;11(10):1361-8
   PubMed Web of Science ®Google Scholar
• Chen X, Lee HF, Zaro JL, Effects of receptor binding on plasma half-life of bifunctional transferrin fusion proteins. Mol Pharm 2011;8(2):457-65
   PubMedGoogle Scholar
• Authier F, Danielsen GM, Kouach M, Identification of insulin domains important for binding to and degradation by endosomal acidic insulinase. Endocrinology 2001;142(1):276-89
   PubMed Web of Science ®Google Scholar
• Smedsrod B, Einarsson M. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver. Thromb Haemost 1990;63(1):60-6
   PubMed Web of Science ®Google Scholar
• Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006;72(1):1-10
   PubMed Web of Science ®Google Scholar
• Ducharme E, Weinberg JM. Etanercept. Expert Opin Biol Ther 2008;8(4):491-502
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58(8):2443-52
   PubMed Web of Science ®Google Scholar
• Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001;28(6):507-32
   PubMed Web of Science ®Google Scholar
• Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 2009;20(6):692-9
   PubMed Web of Science ®Google Scholar
• Schulte S. Half-life extension through albumin fusion technologies. Thromb Res 2009;124(Suppl 2):S6-8
   PubMed Web of Science ®Google Scholar
• Spiegelberg HL, Fishkin BG. The catabolism of human G immunoglobulins of different heavy chain subclasses. 3. The catabolism of heavy chain disease proteins and of Fc fragments of myeloma proteins. Clin Exp Immunol 1972;10(4):599-607
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7(9):715-25
   PubMed Web of Science ®Google Scholar
• Israel EJ, Wilsker DF, Hayes KC, Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 1996;89(4):573-8
   PubMed Web of Science ®Google Scholar
• Anderson CL, Chaudhury C, Kim J, Perspective– FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006;27(7):343-8
   PubMed Web of Science ®Google Scholar
• Chaudhury C, Mehnaz S, Robinson JM, The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003;197(3):315-22
   PubMed Web of Science ®Google Scholar
• Dautry-Varsat A, Ciechanover A, Lodish H. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci USA 1983;80(8):2258-62
   PubMed Web of Science ®Google Scholar
• Morgan E. Effect of pH and iron content of transferrin on its binding to reticulocyte receptors. Biochim Biophys Acta 1983;762(4):498-502
   PubMed Web of Science ®Google Scholar
• De Lorenzo C, D'Alessio G. From immunotoxins to immunoRNases. Curr Pharm Biotechnol 2008;9(3):210-14
   PubMed Web of Science ®Google Scholar
• Khawli LA, Hu P, Epstein AL. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Handb Exp Pharmacol 2008(181):291-328
   PubMedGoogle Scholar
• Pastan II, Kreitman RJ. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev 1998;31(1-2):53-88
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 1998;58(5):968-75
   PubMed Web of Science ®Google Scholar
• Dumont JA, Low SC, Peters RT, Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 2006;20(3):151-60
   PubMed Web of Science ®Google Scholar
• Wang YY, Lui PC, Li JY. Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy 2009;1(6):983-93
   PubMed Web of Science ®Google Scholar
• Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007;24(9):1759-71
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor. J Neurochem 1985;44(6):1771-8
   PubMed Web of Science ®Google Scholar
• Israel EJ, Taylor S, Wu Z, Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 1997;92(1):69-74
   PubMed Web of Science ®Google Scholar
• Hui EK, Boado RJ, Pardridge WM. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol Pharm 2009;6(5):1536-43
   PubMedGoogle Scholar
• Boado RJ, Hui EK, Lu JZ, Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther 2010;333(3):961-9
   PubMed Web of Science ®Google Scholar
• Arai R, Ueda H, Kitayama A, Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng 2001;14(8):529-32
   PubMedGoogle Scholar
• van Kerkhof P, Strous G. The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand. Biochem Soc Trans 2001;29(Pt 4):488-93
   PubMedGoogle Scholar
• Grant B, Donaldson J. Pathways and mechanisms of endocytic recycling. Nat Rev Mol Cell Biol 2009;10(9):597-608
   PubMed Web of Science ®Google Scholar
• Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994;56(3):248-52
   PubMed Web of Science ®Google Scholar
• Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 2005;22(10):1589-96
   PubMed Web of Science ®Google Scholar
• Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 2010;37(1):25-47
   PubMed Web of Science ®Google Scholar
• Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 2010;37(4):323-46
   PubMed Web of Science ®Google Scholar
• Krippendorff BF, Kuester K, Kloft C, Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn 2009;36(3):239-60
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21(3):211-15
   PubMed Web of Science ®Google Scholar
• Barbosa MD. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov Today 2011;16(7-8):345-53
   PubMed Web of Science ®Google Scholar
• Putnam WS, Prabhu S, Zheng Y, Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 2010;28(10):509-16
   PubMed Web of Science ®Google Scholar
• Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther 2007;20(4):270-6
   PubMed Web of Science ®Google Scholar
• Lundquist LM. Abatacept: a novel treatment for rheumatoid arthritis. Expert Opin Pharmacother 2007;8(14):2371-9
   PubMed Web of Science ®Google Scholar
• Cines DB, Yasothan U, Kirkpatrick P. Romiplostim. Nat Rev Drug Discov 2008;7(11):887-8
   PubMed Web of Science ®Google Scholar
• Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 2004;21(11):2105-11
   PubMed Web of Science ®Google Scholar
• Halpern W, Riccobene TA, Agostini H, Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res 2002;19(11):1720-9
   PubMed Web of Science ®Google Scholar
• Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 2007;7(1):11-17
   PubMed Web of Science ®Google Scholar
• Wen X, Lyu MA, Zhang R, Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma. Mol Imaging Biol 2011;13(4):721-9
   PubMed Web of Science ®Google Scholar
• Bang S, Nagata S, Onda M, HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11(4):1545-50
   PubMed Web of Science ®Google Scholar
• Niculescu-Duvaz I. Technology evaluation: EMD-273063, EMD Lexigen. Curr Opin Mol Ther 2004;6(5):559-66
   PubMed Web of Science ®Google Scholar
• Johnson EE, Lum HD, Rakhmilevich AL, Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother 2008;57(12):1891-902
   PubMed Web of Science ®Google Scholar
• Wagner K, Schulz P, Scholz A, The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 2008;14(15):4951-60
   PubMed Web of Science ®Google Scholar
• Halin C, Gafner V, Villani ME, Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003;63(12):3202-10
   PubMed Web of Science ®Google Scholar
• Low SC, Nunes SL, Bitonti AJ, Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod 2005;20(7):1805-13
   PubMed Web of Science ®Google Scholar